TerrAscend Announces the Appointment of Ed Schutter to its Board of Directors

0
55

 

TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced the appointment of Ed Schutter to its Board of Directors.

Mr. Schutter is a seasoned executive with over thirty years of pharmaceutical industry experience. He currently serves as Chief Executive Officer of Arbor Pharmaceuticals (“Arbor”), an Atlanta, Georgia based specialty pharmaceutical company which markets prescription products for the cardiovascular, neuroscience and orphan/hospital markets. Arbor also has several branded prescription products in late stage development.

“We are thrilled to welcome Ed to our Board at such a pivotal time in our Company’s growth,” said Jason Ackerman, Chief Executive Officer and Executive Chairman of TerrAscend. “Ed brings a tremendous amount of relevant Board experience and new ideas to the table. His experience in the U.S. and global pharmaceutical industry will serve TerrAscend well as we continue to build scale and accelerate our growth.”

Jason Wild, Chairman of TerrAscend, added, “As Chairman of Arbor, I have had the pleasure of working with Ed for over 10 years. He is bright, passionate, honest, and genuinely cares about the wellbeing of Arbor’s employees and patients. He has been a source of trusted advice to me, as it relates to TerrAscend over the last three years, and I am thrilled that he has joined our Board. His M&A experience will be particularly useful to us as we continue to grow.”

Prior to joining Arbor, Ed served as President of Sciele (Shionogi) Pharmaceuticals. Prior to Sciele, he served as VP of Global Business development at Solvay Pharmaceuticals based in Basel, Switzerland. He has also held several senior management roles at the U.S. subsidiary of Solvay during his twenty years with the organization. He began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, GA. Mr. Schutter is a registered pharmacist with a degree in Pharmaceutical Sciences from Mercer University and an MBA from Kennesaw State University. He is currently a board member of Arbor, Vitruvias Therapeutics, and Establishment Labs (ESTA) and has been a previous board member of other public, private and non profit organizations.

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

LEAVE A REPLY

Please enter your comment!
Please enter your name here